ArticleMethods in molecular biology (Clifton, N.J.)2026
Peripheral Blood Mononuclear Cell (PBMC) Humanized Mice as a Platform for a Preclinical In Vivo Evaluation of T-Cell-Dependent Bispecific Antibodies.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amid advancements in antibody-based cancer immunotherapy, T-cell-dependent bispecific antibodies (TDBs) hold great promise in cancer treatment. Peripheral blood mononuclear cell (PBMC) humanized mice serve as a platform for preclinical characterization of TDBs, although its induction of xenogeneic graft-versus-host disease (GvHD) limits the experimental time window and introduces confounding factors. NSG-MHC I/II DKO mouse is a highly immunodeficient mouse knocked out for mouse MHC class I and II molecules, which delay GvHD onset following human PBMC engraftment. Here, we describe the materials and methods for generating PBMC humanized mouse models with NSG-MHC I/II DKO mice. Using this model, we demonstrate the feasibility of testing the in vivo efficacy of TDBs in NSG-MHC I/II DKO mice engrafted with the colorectal cancer cell line HT29.
Indexed as
Identifiers
42108352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.